<DOC>
	<DOCNO>NCT01517698</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , parallel-group study investigate efficacy safety RO4917523 adolescent adult patient fragile X syndrome . Patients randomize receive oral dos 0.5 mg 1.5 mg RO4917523 , match placebo daily . The anticipated time study treatment 12 week .</brief_summary>
	<brief_title>A Study RO4917523 Patients With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Adult adolescent patient , 1450 year age Diagnosis fragile X syndrome confirm fragile X mental retardation 1 ( FMR1 ) full mutation qualify score Aberrant Behavior Checklist ( ABC ) CGIS Patients must agree either remain completely abstinent use two effective contraceptive method 3 week study Previous treatment another metabotropic glutamate ( mGLU ) receptor antagonist within 18 month RO4917523 Participation clinical trial involve investigational ( unapproved ) drug within 3 month 5 time halflife ( whichever longer ) start study Any uncontrolled , unstable clinically significant psychiatric condition fragile X syndrome History suicidal behavior</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>